|Bid||6.95 x 1400|
|Ask||6.98 x 1000|
|Day's range||6.94 - 7.21|
|52-week range||3.50 - 24.90|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021 - 15 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||09 Nov 2012|
|1y target est||12.50|
There are a handful of companies that dominate the coronavirus vaccine market. Vaccine hesitancy prevents many people from getting inoculated. One company looking to make headway into the vaccine-hesitant crowd is Vaxart (NASDAQ: VXRT).
Vaxart (NASDAQ: VXRT) soared to stardom when its shares advanced 1,500% last year. The biotech company is developing a coronavirus-vaccine candidate in pill form. With 56% of Americans fully vaccinated, though, your question now may: Will Vaxart be too late to carve out market share?
The stock market continued to gain ground on Thursday, picking up greater momentum as investors started to get more comfortable with the idea of a full economic recovery. A couple of stocks that have played instrumental roles with COVID posted big gains in after-hours trading on Thursday, and what they're saying about their businesses could have implications for the whole stock market. Below, we'll look at why Quidel (NASDAQ: QDEL) and Vaxart (NASDAQ: VXRT) moved sharply upward late Thursday afternoon.